Dr. Reddy’s Laboratories Ltd today announced the launch of Sapropterin Dihydrochloride Oral Solution Powder, 100 mg, the therapeutic equivalent of Kuvan® (Sapropterin Dihydrochloride Dihydrochloride) Powder for Oral Solution, 100 mg, USP, approved by the FDA. (USFDA).
“We are delighted to bring to the market this generic version of Sapropterin Dihydrochloride Oral Solution Powder, demonstrating our continued commitment to making affordable generic medicines available to patients,” said Mark Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy’s Laboratories. “At the same time, this product demonstrates that we are actively expanding the breadth of our portfolio with the treatment of a rare disease.”
Dr. Reddy’s Sapropterin Dihydrochloride Powder for Oral Solution is available in 100mg unit dose sachets in a 30-piece carton.
See Full Prescribing Information.
About Dr. Reddy
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) is an integrated pharmaceutical company committed to providing affordable and innovative medicines for healthier lifestyles. Through its three business lines – pharmaceutical services and active ingredients, global generics and proprietary products – Dr. Reddy’s offers a portfolio of products and services including APIs, customized pharmaceutical services, generics, biosimilars and differentiated formulations. Our main therapeutic areas are the gastrointestinal tract, cardiovascular diseases, diabetology, oncology, pain relief and dermatology. Dr. Reddy works in markets around the world. Our main markets include the USA, India, Russia and the CIS countries, as well as Europe. For more information log into: www.drreddys.com